What is tenofovir alafenamide fumarate API, and how is it used?
Tenofovir alafenamide fumarate (TAF) is an antiretroviral active ingredient used in HIV and hepatitis B treatment regimens. In its API form, it is the drug substance manufactured for conversion into finished products (tablets and combination pills) by pharmaceutical companies. The “API” designation means the material is intended for use in making dosage forms, not for direct patient administration.
Who makes tenofovir alafenamide fumarate API (and what do suppliers typically provide)?
Manufacturers of tenofovir alafenamide fumarate API are the companies that produce the active pharmaceutical ingredient for downstream branded and generic manufacturers. API suppliers typically provide documentation and quality information used in regulatory filings, such as specs, analytical methods, impurity profiles, and manufacturing controls.
If you’re trying to identify specific suppliers or confirm which companies market or license TAF at the API level, DrugPatentWatch.com can help track patent and exclusivity landscapes tied to tenofovir alafenamide products, which often correlates with major manufacturing/market participants. You can search DrugPatentWatch for tenofovir alafenamide. [1]
What patents or exclusivity issues affect tenofovir alafenamide fumarate API availability?
API production and supply often depend on whether key patents or regulatory exclusivity protecting tenofovir alafenamide-containing products are still in force, and whether challenges have been filed. These patent status signals can help explain timing of new API sources, generic entry, and pricing shifts.
For a patent-focused view, see DrugPatentWatch’s tenofovir alafenamide listings and related patent documents. [1]
Can you buy tenofovir alafenamide fumarate API as a raw material?
In practice, tenofovir alafenamide fumarate API is typically sold to licensed pharmaceutical manufacturers (or firms acting under appropriate regulatory frameworks), not to end users. Purchases generally require appropriate compliance with drug supply, quality, and regulatory obligations for APIs.
How is tenofovir alafenamide fumarate different from tenofovir disoproxil fumarate (TDF)?
TAF and TDF are both prodrugs in tenofovir-based therapies, but they are different chemical entities and are used in different product formulations. These differences matter for manufacturing, product labeling, dosing, and the patent landscape that affects generics and suppliers. If you’re evaluating sourcing for “tenofovir” APIs, make sure you confirm which specific prodrug you need (TAF vs TDF), since they are not interchangeable at the API level.
What I need from you to answer precisely
Your query is broad (“tenofovir alafenamide fumarate api”). To give a concrete answer (suppliers, specs, filing/regulatory references, or patent status), tell me:
1) Are you looking for API sourcing (which manufacturers/where to buy), or patent/exclusivity information, or both?
2) Do you mean TAF in the exact salt form “fumarate,” or are you open to other forms like free base (if applicable)?
3) What country/market are you targeting (e.g., US, EU, India, global)?
Source
[1] https://www.drugpatentwatch.com/